Senate Advances IP and Drug Pricing Legislation Amid Innovation Concerns
By EsqSocial Corporation 25/04/25
A Senate panel has advanced three sets of bipartisan bills purportedly aimed at reforming the intellectual property (IP) landscape and lowering the cost of prescription drugs. Together, these bills seek to address issues with product hopping and patent thickets. The bills also seek to improve the efficiency of patent examiners and Food and Drug Administration (FDA) officials, as well as pharmaceutical logistics, through the creation of specific task forces....
By: McCarter & English, LLP